TORONTO, Oct. 3, 2013 /CNW/ - Dymaxium is pleased to welcome Lauren Cuddy and Michael Drummond both as investors and as members of its Board of Directors. Cuddy and
Drummond bring their entrepreneurial spirit, extensive health economics
and outcomes research (HEOR) experience, health care and formulary decision maker (payer) expertise, and business acumen to the Dymaxium team.
The addition of Cuddy and Drummond to the executive team will further
support Dymaxium as it executes on its strategic vision: assisting the
interaction between payers and pharmaceutical and biotechnology
manufacturers through innovative platforms that support making informed
evidence-based product evaluations and formulary decisions to improve
Lauren Cuddy was an executive vice president with OptumInsight (part of
UnitedHealth Group) for the past six years. Previously, she was the
president/CEO of Innovus Research and led its growth from its beginning
as a small Canadian company to becoming the leader in global HEOR
consulting before it was acquired by i3 Ingenix/UnitedHealth Group.
Michael Drummond is one of the world's preeminent thought leaders and
academic consultants in health technology assessment (HTA), HEOR, and
evidence-based decision making. He is a professor at the University of
York in the U.K. and has been a consultant to the World Health
Organization and leading HTA/payer and pharmaceutical industry
Cuddy said, "I am excited to join the team at Dymaxium, as I have always
felt Dymaxium has been one of the most innovative and forward-thinking
companies in this industry. I look forward to working with Allen Lising
and Paul Pijuan to help the company grow and increase its global brand.
I see the same energy and spirit in Dymaxium that we had many years ago
when I led Innovus."
Drummond said, "Evidence-based product evaluations, health technology
assessments, and formulary decision making have been my main interests
over the years. This is something I am passionate about. I believe that
Dymaxium's platforms, especially the FormularyDecisions platform [the
AMCP eDossier System in the U.S.] will further drive innovation in this
field, and I am glad to be part of these developments."
Since 1996, Dymaxium has been an industry leader in providing
interactive solutions to optimize how scientific evidence is presented
to payers. Today, its FormularyDecisions.com® platform is the premier
platform for U.S. formulary decision makers in payer organizations to
request, review, and evaluate the latest information on new and
"Dymaxium has focused on the advancement of 'interfacing with payers'
from traditional HEOR tools to its payer platforms," stated Allen
Lising, managing director and one of the company's co-founders, along
with Paul Pijuan. "We are launching version 2.0 of our payer platform
in November, which will be evolutionary in formulary decision-making
processes and revolutionary in product evaluations. With Lauren and
Mike, we will strive to continue the innovation and look to grow both
in the U.S. and globally."
Lauren Cuddy, MA, MBA, is a senior business leader whose career has ranged from
entrepreneurial startups through to multinational public companies.
Cuddy was a founder of Innovus Research in 1984 and led the company to
a position of global dominance in health economics and outcomes
research before selling the company to OptumInsight, a division of
UnitedHealth Group, in 1996. She held the position of executive vice
president in the Life Sciences division of OptumInsight until 2012.
Lauren has served on a number of boards, including those of McMaster
University, the McMaster Alumni Association, Joseph Brant Memorial
Hospital, the Innovators Alliance, the Golden Horseshoe Biosciences
Network, and the Innovation Factory. She received her MA and MBA from
McMaster University, and was inducted into the McMaster Alumni Gallery
Michael Drummond, BSc, MCom, DPhil, is a professor of health economics and the former
director of the Centre for Health Economics at the University of York
in the U.K. His particular field of interest is in the economic
evaluation of health care treatments and programs. He has undertaken
evaluations in a wide range of medical fields, including eldercare,
neonatal intensive care, immunization programs, services for people
with AIDS, eye health, and pharmaceuticals. He is the author of two
major textbooks and more than 600 scientific papers, has acted as a
consultant to the World Health Organization, and was the project leader
of a European Union project on the Methodology of the Economic
Appraisal of Health Technology. He has been the president of the
International Society of Technology Assessment in Health Care, and of
the International Society for Pharmacoeconomics and Outcomes Research.
He was a member of the Guidelines Review Panels of the National
Institute for Health and Clinical Excellence (NICE) in the U.K. from
2000 to 2011, and is a principal consultant for OptumInsight. In
October 2010, he was made a member of the U.S. Institute of Medicine.
He is currently co-editor-in-chief of Value in Health.
Dymaxium is focused on interfacing with payers, providing both a
FormularyDecisions.com platform for an exclusive community of health
care decision makers in payer organizations and interface tools and
solutions for pharma teams to engage and communicate with payer
Founded in 1996, Dymaxium provides interactive, user-friendly, graphical
tools and solutions to communicate scientific evidence and product
value. It has successfully delivered more than 700 solutions to
pharmaceutical, biotech, and medical device manufacturers in the U.S.,
U.K., Europe, Canada, and Asia.
In 2007, it evolved its vision to directly support payers with its
Outcomes Analyzer platform. The FormularyDecisions.com® platform was
launched in the U.S. in 2010 as the AMCP eDossier System, in
partnership with the Academy of Managed Care Pharmacy (AMCP). Since
then, it has become the premier evidence-based product evaluation
platform in the U.S.
SOURCE: Dymaxium Inc.
For further information:
For more information please contact Sharon Sears.
Telephone: (416) 348-9339 Ext. 233